- Molecular NameCarbinoxamine
- SynonymCarbinoxamine Maleate; Paracarbinoxamine; Paracarinoxamine
- Weight290.794
- Drugbank_IDDB00748
- ACS_NO486-16-8
- Show 2D model
- LogP (experiment)2.17
- LogP (predicted, AB/LogP v2.0)2.83
- pka8.1
- LogD (pH=7, predicted)1.16
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.9
- LogSw (predicted, AB/LogsW2.0)0.51
- Sw (mg/ml) (predicted, ACD/Labs)0.85
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds6
- TPSA25.36
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn H1 class antihistamine.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life10~20 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityCarbinoxamine metabolism involves N-demethylation, deamination, O-dealkylation and conjugation with beta-D-glucuronide. Major metabolites of carbinoxamine are its N-demethylated products N-desmethyl-carbinoxamine and N-didesmethyl-carbinoxamine; (4-chlorophenyl)(pyridin-2-yl)methanol and (4-chlorophenyl)(pyridin-2-yl)methanone are products of O-dealkylation; 3-hydroxy-desaminocarbinoxamine are product of deamination; all metabolites has been detected in human urine after oral administration with carbinoxamine. Glucuronide conjugates of parent drug and its major N-demethylated derivatives also has been detected in human urine.
- LD50 (rat)N/A
- LD50 (mouse)N/A